Literature DB >> 1967583

Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin.

K Kiguchi1, F R Collart, C Henning-Chubb, E Huberman.   

Abstract

The IMP dehydrogenase inhibitors mycophenolic acid (MPA) and tiazofurin (TZ) induce a time- and dose-dependent inhibition of cell growth, as well as differentiation in T-lymphoid CEM-2 leukemia cells. The differentiated cells have acquired a suppressor/cytotoxic T-lymphocyte phenotype characterized by reactivity with maturation-specific monoclonal antibodies. Coadministration of guanosine and hypoxanthine reduces the growth inhibition and diminishes the induction of differentiation by either MPA or TZ. No such reduction was observed for differentiation induced by phorbol 12-myristate 13-acetate (PMA), another inducer of a suppressor/cytotoxic phenotype in CEM-2 cells. During the first 2 days of treatment with MPA or TZ, a pattern of stable IMPDH mRNA levels and increased amounts of cellular enzyme was observed, perhaps, because of compensation for the inhibitor-mediated decrease in cellular IMPDH activity or a MPA- or TZ-mediated decrease in proteolysis of IMPDH. PMA treatment decreased the levels of IMPDH mRNA, protein, and activity. In addition, treatment of CEM-2 cells with either IMPDH inhibitors or PMA caused different alterations of the ribonucleotide pools. The lack of a consistent pattern of IMPDH expression in CEM-2 cells treated with IMPDH inhibitors or PMA indicates that no general association exists between the induction of cell differentiation and the expression of IMPDH. Nevertheless, our results indicating that IMPDH inhibitors can induce differentiation in CEM-2 cells suggest that this treatment may provide a useful approach to circumvent the differentiation block in some tumor cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967583     DOI: 10.1016/0014-4827(90)90114-p

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

Review 1.  IMP dehydrogenase: structure, mechanism, and inhibition.

Authors:  Lizbeth Hedstrom
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

2.  Regulation of IMP dehydrogenase gene expression by its end products, guanine nucleotides.

Authors:  D A Glesne; F R Collart; E Huberman
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

Review 3.  Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.

Authors:  B Fulton; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

4.  Effects of differentiation-inducing agents on purine nucleotide metabolism in an ovarian cancer cell line.

Authors:  E Zoref-Shani; R Lavie; Y Bromberg; E Beery; Y Sidi; O Sperling; J Nordenberg
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.

Authors:  A W Thomson; J Woo; G Z Yao; S Todo; T E Starzl; A Zeevi
Journal:  Transpl Immunol       Date:  1993       Impact factor: 1.708

6.  In silico design of human IMPDH inhibitors using pharmacophore mapping and molecular docking approaches.

Authors:  Rui-Juan Li; Ya-Li Wang; Qing-He Wang; Jian Wang; Mao-Sheng Cheng
Journal:  Comput Math Methods Med       Date:  2015-02-15       Impact factor: 2.238

Review 7.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.